Jaguar health engages b2i digital to deploy cutting-edge investor engagement campaign

Jaguar aims to leverage digital technologies including ai enhancement to help connect with investor communities san francisco, ca / accesswire / august 24, 2023 / jaguar health, inc. (nasdaq:jagx), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (gi) prescription medicines, today announced it has engaged b2i digital to execute an innovative digital investor engagement and awareness program. b2i will harness its investor platform and data-driven digital marketing expertise to highlight jaguar's novel pipeline of prescription drugs sustainably derived from rainforest plants.
JAGX Ratings Summary
JAGX Quant Ranking